NASDAQ:DMTK DermTech (DMTK) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free DMTK Stock Alerts $0.32 -0.01 (-3.02%) (As of 05/30/2024 ET) Add Compare Share Share Today's Range$0.32▼$0.3350-Day Range$0.32▼$0.7152-Week Range$0.30▼$3.90Volume296,745 shsAverage Volume483,656 shsMarket Capitalization$11.22 millionP/E RatioN/ADividend YieldN/APrice Target$2.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DermTech MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside640.6% Upside$2.38 Price TargetShort InterestHealthy8.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.19Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.26) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.89 out of 5 starsMedical Sector661st out of 930 stocksMedical Laboratories Industry16th out of 19 stocks 3.0 Analyst's Opinion Consensus RatingDermTech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageDermTech has only been the subject of 3 research reports in the past 90 days.Read more about DermTech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.94% of the float of DermTech has been sold short.Short Interest Ratio / Days to CoverDermTech has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in DermTech has recently decreased by 7.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDermTech does not currently pay a dividend.Dividend GrowthDermTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMTK. Previous Next 3.4 News and Social Media Coverage News SentimentDermTech has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for DermTech this week, compared to 2 articles on an average week.Search Interest1 people have searched for DMTK on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DermTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of DermTech is held by insiders.Percentage Held by InstitutionsOnly 20.45% of the stock of DermTech is held by institutions.Read more about DermTech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DermTech are expected to grow in the coming year, from ($2.26) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DermTech is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DermTech is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermTech has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about DermTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About DermTech Stock (NASDAQ:DMTK)DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Read More DMTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMTK Stock News HeadlinesMay 15, 2024 | investorplace.comDMTK Stock Earnings: DermTech Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comDermTech GAAP EPS of -$0.58, revenue of $3.85MMay 14, 2024 | finance.yahoo.comDermTech Reports First-Quarter 2024 Financial ResultsApril 20, 2024 | investing.comDermTech stock downgraded by BTIG amid strategic reviewApril 19, 2024 | msn.comBTIG Downgrades DermTech (DMTK)April 19, 2024 | markets.businessinsider.comWhat Analysts Are Saying About DermTech StockApril 18, 2024 | marketwatch.comDermTech to Slash 56% of Workforce, Explore OptionsApril 18, 2024 | msn.comDermTech exploring strategic alternatives, cutting 56% of staffApril 18, 2024 | businesswire.comDermTech to Explore Strategic Alternatives and Implement Restructuring PlanApril 17, 2024 | finance.yahoo.comDermTech, Inc. (DMTK)March 8, 2024 | businesswire.comDermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative DermatologyMarch 7, 2024 | investing.comStephens cuts DermTech stock target to $1.50, keeps Equal Weight ratingMarch 2, 2024 | finance.yahoo.comDermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | benzinga.comRecap: DermTech Q4 EarningsFebruary 29, 2024 | businesswire.comDermTech Reports Fourth-Quarter 2023 Financial ResultsFebruary 28, 2024 | msn.comDermTech Q4 2023 Earnings PreviewFebruary 13, 2024 | finance.yahoo.comDermTech Announces Release Date for Fourth-quarter 2023 Financial ResultsFebruary 1, 2024 | markets.businessinsider.comDermTech International Registered ShsJanuary 31, 2024 | marketwatch.comDermTech to Cut Workforce by 15%, Six Months After Round of LayoffsJanuary 31, 2024 | finance.yahoo.comDermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline OperationsJanuary 18, 2024 | msn.comDermTech study finds melanoma test effective for all skin typesJanuary 18, 2024 | finance.yahoo.comDermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin TypesJanuary 16, 2024 | finance.yahoo.comDermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on AssayJanuary 8, 2024 | marketwatch.comDermTech Shares Rise 14% After Positive Results in Melanoma Test StudyJanuary 8, 2024 | seekingalpha.comDermTech stock rallies 18% on positive study for melanoma testSee More Headlines Company Calendar Last Earnings11/09/2021Today5/30/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:DMTK CUSIPN/A CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees206Year FoundedN/APrice Target and Rating Average Stock Price Target$2.38 High Stock Price Target$5.00 Low Stock Price Target$0.63 Potential Upside/Downside+638.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,890,000.00 Net Margins-572.19% Pretax Margin-572.19% Return on Equity-138.79% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.46 Sales & Book Value Annual Sales$15.30 million Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book0.28Miscellaneous Outstanding Shares34,960,000Free Float33,180,000Market Cap$11.26 million OptionableOptionable Beta2.53 Key ExecutivesMr. Bret Christensen (Age 53)President, CEO & Director Comp: $973.97kMr. Kevin Sun M.B.A. (Age 46)CFO, Treasurer & Secretary Comp: $600.35kMr. Ray Akhavan Esq. (Age 55)J.D., General Counsel Comp: $555.93kMr. William W. ZondlerChief Information OfficerMr. Steve E. KunszaboSenior Director of Investor RelationsMs. Jennifer EilembergChief Compliance OfficerDr. Burkhard Jansen M.D. (Age 58)Chief Medical Affairs Officer Comp: $419.8kDr. Loren Clarke M.D.Chief Medical OfficerDr. Steven Stone Ph.D.Senior Vice President of Research & DevelopmentMr. Mark Aguillard (Age 51)Chief Commercial Officer More ExecutivesKey CompetitorsRenalytixNASDAQ:RNLXExagenNASDAQ:XGNPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCInvitaeNYSE:NVTAView All CompetitorsInsiders & InstitutionsTexas Capital Bank Wealth Management Services IncBought 80,000 shares on 5/13/2024Ownership: 0.578%Kevin M SunSold 447 sharesTotal: $648.15 ($1.45/share)Claudia IbarraSold 331 sharesTotal: $479.95 ($1.45/share)Kevin M SunSold 4,979 sharesTotal: $7,617.87 ($1.53/share)Claudia IbarraSold 3,911 sharesTotal: $5,983.83 ($1.53/share)View All Insider TransactionsView All Institutional Transactions DMTK Stock Analysis - Frequently Asked Questions Should I buy or sell DermTech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DMTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DMTK, but not buy additional shares or sell existing shares. View DMTK analyst ratings or view top-rated stocks. What is DermTech's stock price target for 2024? 3 analysts have issued 12 month price objectives for DermTech's shares. Their DMTK share price targets range from $0.63 to $5.00. On average, they expect the company's share price to reach $2.38 in the next year. This suggests a possible upside of 640.6% from the stock's current price. View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts. How have DMTK shares performed in 2024? DermTech's stock was trading at $1.75 on January 1st, 2024. Since then, DMTK shares have decreased by 81.7% and is now trading at $0.3209. View the best growth stocks for 2024 here. Are investors shorting DermTech? DermTech saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,850,000 shares, a decline of 7.8% from the April 30th total of 3,090,000 shares. Based on an average daily volume of 599,200 shares, the short-interest ratio is presently 4.8 days. Currently, 8.9% of the company's stock are short sold. View DermTech's Short Interest. When is DermTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DMTK earnings forecast. How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.03. The business earned $3.03 million during the quarter, compared to analysts' expectations of $3.40 million. DermTech had a negative net margin of 572.19% and a negative trailing twelve-month return on equity of 138.79%. During the same quarter last year, the firm posted ($0.50) earnings per share. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH). Who are DermTech's major shareholders? DermTech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Texas Capital Bank Wealth Management Services Inc (0.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Claudia Ibarra, Herm Rosenman, John Dobak, Kevin M Sun, Mutual Insurance Co Donegal, Ramin Akhavan, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood. View institutional ownership trends. How do I buy shares of DermTech? Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DMTK) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyGet out of dollars—get into America’s new money insteadStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist My Default Watchlist Adding DermTech, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
